<DOC>
	<DOCNO>NCT00047268</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know whether donor stem cell transplant effective without chemotherapy treat primary myelodysplastic syndrome . PURPOSE : This phase III trial study well donor stem cell transplant give chemotherapy work compare donor stem cell transplant without chemotherapy treat child primary myelodysplastic syndrome .</brief_summary>
	<brief_title>Donor Stem Cell Transplant With Without Chemotherapy Treating Children With Primary Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine , standard approach , frequency different FAB subtypes child primary myelodysplastic syndrome . - Determine frequency cytogenetic molecular abnormality patient . - Determine survival patient treat allogeneic stem cell transplantation without induction chemotherapy . - Determine rate complete remission patient treat regimen . - Determine event-free survival patient treat regimen . - Determine relapse rate , morbidity , mortality patient treat regimen . - Determine different subset patient benefit regimen . OUTLINE : This multicenter study . Patients stratify accord FAB subtype ( refractory anemia ( RA ) RA ring sideroblast ( RARS ) v RA excess blast ( RAEB ) v RAEB transformation ( RAEB-t ) v juvenile myelomonocytic leukemia ( JMML ) ) . Patients undergo complete medical physical examination . Patients screen follow aberration : -7 , +8 , +21 , ( 8 ; 21 ) , ( 15 ; 17 ) , inv ( 16 ) . Smears peripheral blood bone marrow , well bone marrow biopsy cytogenetic molecular study perform blood bone marrow , evaluate panel international expert . Patients progressive RA RARS undergo allogeneic stem cell transplantation ( ASCT ) accord EWOG-MDS SCT study . Patients stable RA RARS wait optimal donor undergo ASCT . Patients RAEB few 15 % bone marrow blast undergo ASCT . Patients RAEB least 15 % bone marrow blast patient RAEB-t few 30 % bone marrow blast receive standard acute myeloid leukemia ( AML ) induction therapy undergo ASCT . Patients RAEB-t least 30 % bone marrow blast consider standard AML induction therapy . Patients advance JMML undergo evaluation splenectomy receive chemotherapy mercaptopurine cytarabine every 3-4 week ( 1-4 dos ) . Patients undergo ASCT . Patients follow every 6 month . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm primary myelodysplastic syndrome ( MDS ) Diagnosed July 1 , 1998 June 30 , 2002 No prior aplastic anemia No prior congenital bone marrow failure syndrome , : Fanconi 's anemia Kostmann syndrome Shwachman syndrome Dyskeratosis congenital Amegakaryocytic thrombocytopenia DiamondBlackfan anemia No Down syndrome None follow cytogenetic molecular abnormality : ( 8 ; 21 ) ( q22 ; q22 ) ( 15 ; 17 ) ( q22 ; q12 ) inv ( 16 ) ( p13 ; q22 ) No typical clinical cytogenetic feature acute myeloid leukemia FAB M7 ( i.e. , acute megakaryocytic leukemia ) few 30 % blast bone marrow peripheral blood PATIENT CHARACTERISTICS : Age Under 19 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Other No concurrent illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy MDS Endocrine therapy Not specify Radiotherapy No prior radiotherapy MDS Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>